Omnicell, Inc. (OMCL) Stake Increased by King Luther Capital Management Corp

King Luther Capital Management Corp increased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 11.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,605 shares of the company’s stock after purchasing an additional 8,215 shares during the period. King Luther Capital Management Corp’s holdings in Omnicell were worth $5,652,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in OMCL. Ibex Investors LLC bought a new stake in Omnicell during the 3rd quarter valued at about $209,000. Riverhead Capital Management LLC lifted its holdings in Omnicell by 34.5% during the 3rd quarter. Riverhead Capital Management LLC now owns 7,400 shares of the company’s stock valued at $532,000 after buying an additional 1,900 shares in the last quarter. Axiom International Investors LLC DE lifted its holdings in Omnicell by 195.5% during the 3rd quarter. Axiom International Investors LLC DE now owns 72,153 shares of the company’s stock valued at $5,188,000 after buying an additional 47,733 shares in the last quarter. Allianz Asset Management GmbH lifted its holdings in Omnicell by 518.9% during the 3rd quarter. Allianz Asset Management GmbH now owns 124,170 shares of the company’s stock valued at $8,928,000 after buying an additional 104,107 shares in the last quarter. Finally, Bellevue Group AG lifted its holdings in Omnicell by 63.7% during the 3rd quarter. Bellevue Group AG now owns 104,650 shares of the company’s stock valued at $7,524,000 after buying an additional 40,705 shares in the last quarter.

NASDAQ:OMCL opened at $69.83 on Friday. Omnicell, Inc. has a one year low of $39.75 and a one year high of $79.48. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.32. The stock has a market capitalization of $2.80 billion, a PE ratio of 387.94, a price-to-earnings-growth ratio of 4.22 and a beta of 0.99.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, October 25th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.40 by $0.09. Omnicell had a net margin of 6.11% and a return on equity of 7.91%. The business had revenue of $204.27 million during the quarter, compared to analyst estimates of $203.48 million. Research analysts forecast that Omnicell, Inc. will post 1.42 earnings per share for the current year.

A number of equities research analysts recently weighed in on OMCL shares. Craig Hallum lifted their price objective on shares of Omnicell from $65.00 to $80.00 and gave the company a “buy” rating in a report on Monday, September 17th. Zacks Investment Research upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a report on Monday, August 13th. Cantor Fitzgerald lifted their price objective on shares of Omnicell from $63.00 to $70.00 and gave the company an “overweight” rating in a report on Friday, October 26th. MED lifted their price objective on shares of Omnicell from $59.00 to $71.00 and gave the company an “in-line” rating in a report on Monday, October 22nd. Finally, Benchmark boosted their price target on shares of Omnicell from $66.00 to $79.00 and gave the company a “buy” rating in a report on Friday, October 5th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. Omnicell presently has a consensus rating of “Buy” and an average price target of $73.75.

In other news, CFO Peter J. Kuipers sold 5,574 shares of the business’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $68.87, for a total value of $383,881.38. Following the completion of the sale, the chief financial officer now owns 51,542 shares in the company, valued at approximately $3,549,697.54. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James T. Judson sold 5,000 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $71.18, for a total transaction of $355,900.00. Following the completion of the sale, the director now owns 29,952 shares of the company’s stock, valued at approximately $2,131,983.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 19,267 shares of company stock valued at $1,309,116. Company insiders own 3.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Omnicell, Inc. (OMCL) Stake Increased by King Luther Capital Management Corp” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2018/12/08/omnicell-inc-omcl-stake-increased-by-king-luther-capital-management-corp.html.

Omnicell Profile

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Featured Article: Cost of Equity

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit